Drugs / CHP-NY-ESO-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00291473 | Jul 2005 → Aug 2008 | breast cancer, esophageal cancer, gastric cancer, lung cancer +1 | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHP-NY-ESO-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00291473 ↗ |
| Modality | Protein / enzyme biologic | “CHP-NY-ESO-1 protein” NCT00291473 ↗ |
| Route | Subcutaneous | “CHP-HER2 and CHP-NY-ESO-1 are subcutaneously given on bimonthly basis” NCT00291473 ↗ |